Member Info for DShox

PIs, punters and players DYOR.

Question whether any institutional investor would post any indication of position or final price on this bulletin board.

The sale process nor the share price has completed its journey, and explicitly suggesting it has in anticipation of deal execution at a set price is not the hallmark of a professional.

Two points only
- EUA has been investing heavily into technical studies and WK plant for one purpose, to assist complete company disposal and maximise sale price. It is not a "close call" regarding cash held prior to the fundraise.
- EUA has strategically funded WK to ramp-up to 65koz pa target with both plant and DFS, thereby presenting a clean, self sufficient project for bidders.

The sells can reflect stock purchased. If I buy 100k, you'll see 100k also appear as a sell.

1 hr later but why not have a little flourish into the close

Going up

Either way, its August and plenty of work going on in the meantime. If we are counting the weeks, it makes no difference to me.

Logical that attainment of the Flanks is an important Condition Precedent.

nm

No large sells urking in the background, unlike yesterday. Strength in the Bid.

Its below mid price - nothing sinister. I added at 4.6p. Slowly building a meaningful holding. You might look back and be very pleased you had the foresight to buy well before the herds.

Actual spread. Dummy quotes.

Thanks and agree but one or two are choosing to miss the point. SC is transformational given the current market cap and stage of IQ-AI. With new found financial strength, IB can push on to commercialisation with all the other leveraged opportunities incl Telemedicine and Gad-free.

David Smith interview back in 2018 talked about $1.2bn pa in the US alone in 2017 being spent on these contrast agents, used in 50% of scans to help the radiologist spot the problem. He then pointed out the disease that can follow as a result of gadolidium toxicity and inevitable lawsuits.

IQAI has a few items to hit on Gad-free according to May RNS, but will be a game-changer if IQAI's AI can completely replace use of gadolidium contrast agents.

Don't worry, I'll take you to task as you deramp the low volume. Don't get upset.

I'm just going to fetch my other ID to reply to me and help me rebuild credibility before the re-rate ;)

Let's see whether we beat Wolves' $400k for StoneChecker and 9p price target :) I think many well research PI sees StoneChecker sale as a springboard to a sustainably higher share price to develop the main event IB, not forgetting Gad-free.

Erm well you say that Wolves, but since you've been busy replying intricately since Friday afternoon when you allegedly filtered me...anyway, GL with your short. It will help my very, very short journey to profitability.

Yes I'm a little down having bought in the 4s and 5s so looking forward to massive gains as Wolves points out, though I'm concerned Wolves is going to get hammered by his over extended short.

That's an easy 65% for PIs buying now then. Almost "free" when the deal lands! Thanks Wolves - accidentally started to "ramp" IQAI lol

Wolves' says many on here think StoneChecker is $100m deal - who are the many? Personally $100m is more likely than Wolves' $400k ;)

He is "concerned" for PIs. This dude! lol

At £7m cap, anything more than Wolves' $400k deramp is transformational. IQ-AI could suddenly move from loss maker to profit maker (royalty component of deal) with lots of cash in the bank (cash component of deal).

Listen in to the David Smith interview of Nov 18. IQ-AI has been talking to majors for years to ensure StoneChecker is a neat fit with their requirements and 3 year development cycles.